Eloxx Pharmaceuticals (NASDAQ:ELOX) and Harmony Biosciences (NASDAQ:HRMY) Financial Review

Harmony Biosciences (NASDAQ:HRMY) and Eloxx Pharmaceuticals (NASDAQ:ELOX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.

Risk and Volatility

Harmony Biosciences has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Harmony Biosciences and Eloxx Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1	5	5	0	2.36
Eloxx Pharmaceuticals	1	0	2	1	2.75

Harmony Biosciences presently has a consensus price target of $47.11, suggesting a potential upside of 13.41%. Eloxx Pharmaceuticals has a consensus price target of $41.50, suggesting a potential upside of 154.60%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Harmony Biosciences.

Earnings & Valuation

This table compares Harmony Biosciences and Eloxx Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$959.90 million	2.52	$158.69 million	$3.08	13.49
Eloxx Pharmaceuticals	$6.36 million	10.35	-$5.99 million	($1.54)	-10.58

Harmony Biosciences has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Harmony Biosciences and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Eloxx Pharmaceuticals	N/A	N/A	N/A

Institutional and Insider Ownership

86.2% of Harmony Biosciences shares are held by institutional investors. Comparatively, 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Harmony Biosciences beats Eloxx Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.